Healthcare is broken in the USA – But Pharma can lead the way to a new sustainable model
As we enter election year in 2020, the pressure has never been higher on our industry to justify what we add to the cost of healthcare. Price control has become a bipartisan issue and across the wide-range of policy positions that are on the table in Fall 2020, one area is clear: the transition towards value-based care is inevitable.
Compared to last decade, when we were rightly taken to task for bloated pipelines with costly ‘me-too’ treatments, the situation couldn’t be more different. We are on the verge of a new golden age for R&D. Personalized care is starting to deliver. Innovations in cell gene, Car-T and curative therapies offer transformative impact to patients. The problem is: they are also very expensive.
Let’s get ahead of this crisis and come together to define a better way forward.
eyeforpharma Philadelphia 2020 takes place between April 15-16. Join 1,200 + of your peers at North America's largest commercial pharma conference!